Natixis Advisors, L.P. Biomarin Pharmaceutical Inc Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$74.43 - $92.22 $2.72 Million - $3.37 Million	-36,548 Reduced 65.91%	18,901 $1.56 Million
Q1 2024 Apr 25, 2024	SELL	$83.81 - $99.0 $349,487 - $412,830	-4,170 Reduced 6.99%	55,449 $4.84 Million
Q4 2023 Feb 06, 2024	SELL	$76.22 - $98.51 $18,902 - $24,430	-248 Reduced 0.41%	59,619 $5.75 Million
Q3 2023 Nov 13, 2023	BUY	$85.07 - $94.48 $9,868 - $10,959	116 Added 0.19%	59,867 $5.3 Million
Q2 2023 Aug 15, 2023	SELL	$86.68 - $100.3 $104,622 - $121,062	-1,207 Reduced 1.98%	59,751 $5.18 Million
Q1 2023 May 11, 2023	SELL	$87.74 - $117.27 $121,695 - $162,653	-1,387 Reduced 2.22%	60,958 $5.93 Million
Q4 2022 Jan 27, 2023	SELL	$80.93 - $108.63 $1.07 Million - $1.44 Million	-13,239 Reduced 17.52%	62,345 $6.45 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $589,169 - $695,156	7,171 Added 10.48%	75,584 $6.41 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $575,199 - $698,881	8,047 Added 13.33%	68,413 $5.67 Million
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $298,308 - $372,243	-4,016 Reduced 6.24%	60,366 $4.65 Million
Q4 2021 Feb 08, 2022	BUY	$71.72 - $91.47 $635,941 - $811,064	8,867 Added 15.97%	64,382 $5.69 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.89 Million - $2.16 Million	25,314 Added 83.82%	55,515 $4.29 Million
Q2 2021 Aug 12, 2021	BUY	$75.51 - $84.79 $765,444 - $859,516	10,137 Added 50.52%	30,201 $2.52 Million
Q1 2021 May 05, 2021	SELL	$74.73 - $90.69 $2.58 Million - $3.14 Million	-34,582 Reduced 63.28%	20,064 $1.52 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $1.23 Million - $1.53 Million	16,968 Added 45.03%	54,646 $4.79 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $298,476 - $544,167	4,153 Added 12.39%	37,678 $2.87 Million
Q2 2020 Aug 11, 2020	BUY	$79.55 - $124.22 $1.44 Million - $2.24 Million	18,053 Added 116.68%	33,525 $4.14 Million
Q1 2020 Apr 27, 2020	BUY	$71.37 - $96.85 $129,465 - $175,685	1,814 Added 13.28%	15,472 $1.31 Million
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $877,799 - $1.18 Million	13,658 New	13,658 $1.16 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $1.99 Million - $2.51 Million	-29,499 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $316,820 - $370,247	-3,943 Reduced 11.79%	29,499 $2.53 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $36,542 - $42,801	434 Added 1.31%	33,442 $2.97 Million
Q4 2018 Feb 13, 2019	SELL	$80.14 - $106.07 $59,544 - $78,810	-743 Reduced 2.2%	33,008 $2.81 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $103,781 - $116,820	-1,105 Reduced 3.17%	33,751 $3.27 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $1.33 Million - $1.73 Million	17,437 Added 100.1%	34,856 $0
Q1 2018 May 10, 2018	SELL	$77.67 - $92.63 $33,398 - $39,830	-430 Reduced 2.41%	17,419 $1.41 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $969 - $1,141	12 Added 0.07%	17,849 $1.59 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1.44 Million - $1.69 Million	17,837	17,837 $1.66 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account